References
- Albihn A, Johnsen JI, Henriksson MA (2010). MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res, 107, 163-224 https://doi.org/10.1016/S0065-230X(10)07006-5
- American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society, 2012. Available online. Last accessed November 23, 2012.
- Barathidasan R, Pawaiya RS, Rai RB, et al (2013). Upregulated myc expression in n-methyl nitrosourea (MNU)-induced rat ma mmary tumours. Asian Pac J Cancer Prev, 14, 4883-9. https://doi.org/10.7314/APJCP.2013.14.8.4883
- Doe MR, Ascano JM, Kaur M, et al (2012). Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res, 72. 949-57. https://doi.org/10.1158/0008-5472.CAN-11-2371
- Fang YQ, Sun HK, Zhai J, et al (2011). Antitumor Activity of NF-kB Decoy Oligodeoxynucleotides in a Prostate Cancer Cell Line. Asian Pacific J Cancer Prev, 12, 2721-6.
- Guo WQ, Li LZ, He ZY, et al (2013). Anti-proliferative Effects of Atractylis lancea (Thunb.) DC. via Down-regulation of the c-myc/hTERT/telomerase pathway in Hep-G2 cells. Asian Pac J Cancer Prev, 14, 6363-7. https://doi.org/10.7314/APJCP.2013.14.11.6363
- Hayashi D (1994). Study on the expression of oncogene mRNA in hepatocellular carcinoma using in situ hybridization technique. Nihon Geka Gakkai Zasshi. 95, 814-22.
- Hemann MT, Bric A, Teruya-Feldstein J, et al (2005). Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 436, 807-11. https://doi.org/10.1038/nature03845
- Howlader N, Noone AM, Krapcho M, et al (2011), eds.:SEER Cancer Statistics Review, 1975-2008. Bethesda, Md: National Cancer Institute, 2011. Also available online. Last accessed July, 31, 2012.
- Jain M, Arvanitis C, Chu K, et al (2002). Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science, 297, 102-4. https://doi.org/10.1126/science.1071489
- Jansen B, Zangemeister-Wittke U (2002). Antisense therapy for cancer--the time of truth. Lancet Oncol, 3, 672-83. https://doi.org/10.1016/S1470-2045(02)00903-8
- Jin J, Huang M, Wei HL et al (2002). Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel (7402). World J Gastroenterol, 8. 1029-34.
- Karlsson A, Giuriato S, Tang F, et al (2003). Genomically complex lymphomas undergo sustained tumor regression upon MY inactivation unless they acquire novel chromosomal translocations. Blood, 101, 2797-803. https://doi.org/10.1182/blood-2002-10-3091
- Lin CP, Liu CR, Lee CN, et al (2010). Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol, 2. 16-20.
- Manner J, Radlwi mmer B, Hohenberger P, et al (2010). MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol, 176, 34-9. https://doi.org/10.2353/ajpath.2010.090637
- Monia BP (1997). First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des, 12, 327-39.
- Parkin DM, Whelan SL, Ferlay J, et al (1997). eds.:Cancer Incidence in Five Continents. Volume VII. Lyon, France:International Agency for Research on Cancer
- Pastorino F, Mumbengegwi DR, Ribatti D, et al (2008). Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release, 126, 85-94. https://doi.org/10.1016/j.jconrel.2007.11.010
- Wang B, Hikosaka K, Sultana N, et al (2012). Liver tumor formation by a mutant retinoblastoma protein in the transgenic mice is caused by an upregulation of c-My target genes. Biochem Biophys Res Co mmun, 417, 601-6. https://doi.org/10.1016/j.bbrc.2011.12.014
- Wang C, Lisanti MP, Liao DJ (2011). Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1- CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle, 10, 57-67. https://doi.org/10.4161/cc.10.1.14449
- Wu SL, Sun ZJ, Yu L, et al (2004). Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol, 10, 3048-52.
- Yang Y, Lv QJ, Du QY, et al (2005). Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol, 11, 2491-6. https://doi.org/10.3748/wjg.v11.i16.2491
- Yochum GS, Sherrick CM, Macpartlin M, et al (2010). A betacatenin/ TCF- coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers. Proc Natl Acad Sci USA, 107, 145-50. https://doi.org/10.1073/pnas.0912294107
Cited by
- Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy vol.16, pp.2, 2017, https://doi.org/10.3892/mmr.2017.6778